Constantine Tam, Andrzej Mital, Robert Weinkove, Wojciech Jurczak, Xin Yan, Nataliya Kuptsova-Clarkson, Tian Tian, Megan Wang, Jamie Hirata. "Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)." Blood, 2025. doi:10.1182/blood-2025-2123